CTOs on the Move

Analgesic Solutions

www.analgesicsolutions.com

 
Analgesic Solutions, LLC., founded in 2006, is a privately held consulting company and Clinical Research Organization. We are a hands-on team of experts across a variety of disciplines who consult on and conduct clinical trials aimed at bringing important new pain treatments to market. With hundreds of projects completed and ongoing collaborations with regulatory authorities, Analgesic Solutions is the premier choice for providing assistance and training to insure successful pain trials. Clients come to us when looking to develop and commercialize better treatments for pain. Our team, with Nathaniel Katz M.D., M.S., serving as our foremost expert, helps ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Arturo Morales
Chief Technology Officer Profile

Similar Companies

Comparative Biosciences Inc

Comparative Biosciences Inc is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abece

Abece is a Miami Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beckman Coulter

Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.

Biotechlogic

Biotechlogic is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.